Skip to main content
. Author manuscript; available in PMC: 2012 Dec 8.
Published in final edited form as: Cancer Lett. 2011 Aug 6;311(2):219–229. doi: 10.1016/j.canlet.2011.07.023

Figure 4. Drug concentrations in normal tissue.

Figure 4

Panel A shows irinotecan or SN-38 concentrations in large intestine, small intestine, bone marrow, kidneys and liver 2h after treatment with 100mg/kg irinotecan alone graphic file with name nihms316771ig1.jpg, or concurrent combination treatment of MSC (0.2 mg/d) and irinotecan graphic file with name nihms316771ig2.jpg.

Panel B shows irinotecan and SN-38 concentrations in large intestine or small intestine 2h after the second course of 100mg/kg irinotecan alone graphic file with name nihms316771ig1.jpg, or in combination with MSC graphic file with name nihms316771ig2.jpg.

When compared with irinotecan alone, the only significant change in drug concentration was a decrease in large intestine SN-38 concentration in panel A (p<0.05). * denotes p < 0.05 when compared to irinotecan alone.